Home / Market News / $MIST
benzinga Corporate Catalyst Impact 75/100 ● positive

Milestone Pharmaceuticals Says China’s National Medical Products Administration Approves Etripamil Nasal Spray For Treatment Of Paroxysmal Supraventricular Tachycardia In Adults

Sep 3, 2026, 1:36 PM UTC · Primary ticker $MIST

Milestone Pharmaceuticals announced that China's NMPA approved its etripamil nasal spray for PSVT, triggering a $2.0 million milestone payment. This approval opens a significant new market for the drug and strengthens Milestone's partnership with Everest Medicines in Greater China.

Milestone Pharmaceuticals (MIST) announced a significant regulatory win with the NMPA approval of its etripamil nasal spray in China for Paroxysmal Supraventricular Tachycardia (PSVT). This approval is a major positive catalyst for MIST, triggering a $2.0 million milestone payment and opening up a new, large market estimated at 3-6 million patients. Everest Medicines (1952.HK), MIST's partner in Greater China, will lead commercialization and stands to benefit significantly from sales, with MIST also eligible for up to $98.0 million in additional milestones and tiered royalties up to 18%. This long-term opportunity for revenue growth and market penetration is a strong positive for both companies, especially MIST, as it validates their drug outside the US and diversifies their revenue streams.

$MIST positive Drug approval, milestone payment, market expansion
$1952.HK positive Commercialization rights, potential for significant sales
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.